ECSP21038390A - Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr - Google Patents

Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr

Info

Publication number
ECSP21038390A
ECSP21038390A ECSENADI202138390A ECDI202138390A ECSP21038390A EC SP21038390 A ECSP21038390 A EC SP21038390A EC SENADI202138390 A ECSENADI202138390 A EC SENADI202138390A EC DI202138390 A ECDI202138390 A EC DI202138390A EC SP21038390 A ECSP21038390 A EC SP21038390A
Authority
EC
Ecuador
Prior art keywords
compounds
inhibitors
preparation
methods
pharmaceutical compositions
Prior art date
Application number
ECSENADI202138390A
Other languages
English (en)
Inventor
Paul Jones
Cyrus M Lacbay
Vouy Linh Truong
Jean-François Truchon
Sheldon N Crane
Miguel St-Onge
Lee Fader
Cameron Black
Stéphanie Lanoix
Audrey Picard
Abbas Abdoli
Stéphane Dorich
Original Assignee
Repare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repare Therapeutics Inc filed Critical Repare Therapeutics Inc
Publication of ECSP21038390A publication Critical patent/ECSP21038390A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen compuestos y sales farmacéuticamente aceptables de estos que se pueden usar en el tratamiento de sujetos que los necesitan. Los compuestos descritos en la presente pueden ser inhibidores de la proteína cinasa relacionada con ataxia telangiectasia y RAD3 (ATR). También se describen composiciones farmacéuticas que contienen los compuestos o sales farmacéuticamente aceptables de estos y métodos para su preparación y uso.
ECSENADI202138390A 2018-10-30 2021-05-28 Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr ECSP21038390A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862752873P 2018-10-30 2018-10-30
US201962877177P 2019-07-22 2019-07-22

Publications (1)

Publication Number Publication Date
ECSP21038390A true ECSP21038390A (es) 2021-08-31

Family

ID=70461742

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202138390A ECSP21038390A (es) 2018-10-30 2021-05-28 Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr

Country Status (17)

Country Link
US (2) US12264155B2 (es)
EP (1) EP3873905A4 (es)
JP (2) JP2022510501A (es)
KR (1) KR20210097124A (es)
CN (2) CN113454080B (es)
AU (1) AU2019373416A1 (es)
BR (1) BR112021008336A2 (es)
CA (1) CA3118218A1 (es)
CR (1) CR20210281A (es)
EC (1) ECSP21038390A (es)
IL (1) IL282801A (es)
MA (1) MA54091A (es)
MX (1) MX2021005012A (es)
PH (1) PH12021550992A1 (es)
SG (1) SG11202104460UA (es)
WO (1) WO2020087170A1 (es)
ZA (1) ZA202103587B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019373416A1 (en) 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
CN112142744A (zh) 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
KR20220035925A (ko) * 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
EP4072551A4 (en) * 2019-12-11 2023-11-15 Repare Therapeutics Inc. USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS
BR112022012130A2 (pt) * 2019-12-18 2022-08-30 Intervet Int Bv Compostos antelmínticos compreendendo uma estrutura azaindólica
WO2022002243A1 (zh) * 2020-07-02 2022-01-06 江苏恒瑞医药股份有限公司 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用
IL299804A (en) * 2020-07-13 2023-03-01 Beijing Tide Pharmaceutical Co Ltd Pyrazolopyrimidine compounds for use as ATR kinase inhibitors
TW202220993A (zh) * 2020-08-07 2022-06-01 香港商德琪研發有限公司 Atr抑制劑及其用途
US20240043419A1 (en) * 2020-09-27 2024-02-08 Medshine Discovery Inc. Class of 1,7-naphthyridine compounds and application thereof
JP2024516821A (ja) * 2021-04-28 2024-04-17 リペア セラピューティクス インコーポレイテッド 両アレル機能喪失型変異または遺伝子過剰発現変異を有するがんを治療する方法
AU2022271549A1 (en) * 2021-05-12 2023-11-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Sulfoximine-containing atr inhibitor compound
BR112023024942A2 (pt) * 2021-06-16 2024-02-15 Repare Therapeutics Inc Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer
TW202321256A (zh) 2021-07-27 2023-06-01 大陸商上海輝啟生物醫藥科技有限公司 ８－氧－３－氮雜雙環［３．２．１］辛烷類化合物或其鹽及其製備方法和用途
WO2023016529A1 (zh) * 2021-08-11 2023-02-16 微境生物医药科技(上海)有限公司 作为atr抑制剂的萘啶衍生物及其制备方法
WO2023109883A1 (zh) * 2021-12-15 2023-06-22 上海翊石医药科技有限公司 一类芳杂环取代的化合物及其制备方法和用途
CN119212710A (zh) * 2022-04-07 2024-12-27 修复治疗公司 使用atr抑制剂的方法
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202440598A (zh) 2022-12-07 2024-10-16 瑞士商赫孚孟拉羅股份公司 Ａｔｒ抑制劑之結晶鹽形式
CN119143753B (zh) * 2023-06-14 2026-01-02 石药集团中奇制药技术（石家庄）有限公司 一种杂环类抗肿瘤化合物的盐及其晶型
WO2025057106A1 (en) * 2023-09-12 2025-03-20 Repare Therapeutics Inc. Process and compounds for preparing camonsertib and its salts
CN121969626A (zh) * 2023-09-27 2026-05-01 苏州必扬医药科技有限公司 一种Menin-MLL相互作用抑制剂及其制备方法和应用
TW202545519A (zh) * 2024-05-15 2025-12-01 俄羅斯聯邦商拜奧卡德聯合股份公司 共濟失調毛細血管擴張症和Ｒａｄ３相關激酶抑制劑

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495541B1 (en) 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
US20060276497A1 (en) 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US20040048866A1 (en) * 2002-03-08 2004-03-11 Teodozyj Kolasa Indazole derivatives that are activators of soluble guanylate cyclase
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
PL2305221T3 (pl) 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
BRPI0814503A2 (pt) 2007-07-09 2017-05-16 Astrazeneca Ab composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
ES2504690T3 (es) 2007-10-03 2014-10-08 Eisai Inc. Compuestos inhibidores de PARP, composiciones y métodos de uso
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
CN104478875B (zh) 2008-08-06 2017-04-12 麦迪韦逊科技有限公司 聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
US20110053923A1 (en) 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
CA2767008C (en) 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
EA030141B1 (ru) * 2009-12-31 2018-06-29 Хатчисон Медифарма Лимитед Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
EP4166558A1 (en) 2010-02-12 2023-04-19 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
MX2013011450A (es) 2011-04-05 2014-02-03 Vertex Pharma Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
EP2755962B1 (en) * 2011-09-13 2017-03-01 Glaxosmithkline LLC Azaindazoles
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
US8906910B2 (en) * 2011-12-20 2014-12-09 Glaxosmithkline Llc Imidazopyridine derivatives as PI3 kinase
CN108478577A (zh) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3022195A2 (en) 2013-07-19 2016-05-25 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
ES2919024T3 (es) 2014-02-11 2022-07-21 Mitokinin Inc Composiciones y procedimientos que utilizan las mismas para el tratamiento de enfermedades neurodegenerativas y mitocondriales
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
KR102569226B1 (ko) 2014-10-13 2023-08-22 아트린 파마슈티컬스 엘엘씨 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제
ES2865330T3 (es) * 2015-04-29 2021-10-15 Janssen Pharmaceutica Nv Azabenzimidazoles y su uso como moduladores del receptor AMPA
WO2016183519A1 (en) 2015-05-14 2016-11-17 The Regents Of The University Of California Brassinosteroid mimetics
WO2017118734A1 (en) 2016-01-08 2017-07-13 The Institute Of Cancer Research: Royal Cancer Hospital Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (atr) for use in methods of treating cancer
CA3011189C (en) * 2016-01-14 2024-02-20 Bayer Pharma Aktiengesellschaft 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
WO2017133657A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017202748A1 (en) 2016-05-24 2017-11-30 Merck Patent Gmbh Tricyclic heterocylic derivatives
US11660301B2 (en) 2017-02-24 2023-05-30 Bayer Pharma Aktiengesellschaft Combination of ATR kinase inhibitors with PARP inhibitors
JOP20190197A1 (ar) 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
JP7290627B2 (ja) 2017-08-17 2023-06-13 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
CN112654396B (zh) 2018-09-07 2025-07-01 默克专利股份公司 5-吗啉-4-基-吡唑并[4,3-b]吡啶衍生物
AU2019373416A1 (en) 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
CN112142744A (zh) 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
KR20220035925A (ko) 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
EP4072551A4 (en) 2019-12-11 2023-11-15 Repare Therapeutics Inc. USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS
JP2024516821A (ja) 2021-04-28 2024-04-17 リペア セラピューティクス インコーポレイテッド 両アレル機能喪失型変異または遺伝子過剰発現変異を有するがんを治療する方法
MX2023014302A (es) 2021-06-04 2024-02-28 Repare Therapeutics Inc Formas cristalinas, composiciones que contienen las mismas y métodos para su uso.
BR112023024942A2 (pt) 2021-06-16 2024-02-15 Repare Therapeutics Inc Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer
CN119212710A (zh) 2022-04-07 2024-12-27 修复治疗公司 使用atr抑制剂的方法
WO2023193110A1 (en) 2022-04-07 2023-10-12 Repare Therapeutics Inc. Methods of identifying cancers having a biallelic loss of function mutation
TW202440598A (zh) 2022-12-07 2024-10-16 瑞士商赫孚孟拉羅股份公司 Ａｔｒ抑制劑之結晶鹽形式

Also Published As

Publication number Publication date
US12264155B2 (en) 2025-04-01
JP2024105340A (ja) 2024-08-06
EP3873905A1 (en) 2021-09-08
EP3873905A4 (en) 2022-08-17
BR112021008336A2 (pt) 2021-08-03
US20210277002A1 (en) 2021-09-09
CN113454080A (zh) 2021-09-28
CR20210281A (es) 2021-10-25
MX2021005012A (es) 2021-07-21
JP2022510501A (ja) 2022-01-26
SG11202104460UA (en) 2021-05-28
WO2020087170A1 (en) 2020-05-07
US20250179070A1 (en) 2025-06-05
IL282801A (en) 2021-06-30
MA54091A (fr) 2021-09-15
CN120665067A (zh) 2025-09-19
PH12021550992A1 (en) 2021-10-04
ZA202103587B (en) 2025-09-25
CN113454080B (zh) 2025-10-28
KR20210097124A (ko) 2021-08-06
AU2019373416A1 (en) 2021-06-10
CA3118218A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
CO2022015638A2 (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
BR112022007612A2 (pt) Inibidores de raf quinases
MX2021009673A (es) Moduladores de ror-gamma.
CY1121195T1 (el) Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
CR20190124A (es) Inhibidores de ssao de aminopirimidina
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
MX2018013387A (es) Inhibidores de la arginasa y sus aplicaciones terapeuticas.
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
MX2020013320A (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos.
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
MX395032B (es) Ciertos inhibidores de la proteína quinasa.
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
MX2019000159A (es) Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]pirida zin-4-onas como inhibidores de la proteina quinasa.
DOP2025000073A (es) Combinación de compuestos de 2,4 diamino-quinolina sustituida e inhibidores de la proteína quinasa quinasa activada por mitógeno (mek) para ser utilizada en el tratamiento de cánceres hepáticos